Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Newborn Screening for Pompe Disease
| Newborn Screening for Pompe Disease |
| Autore | Hwu Wuh-Liang |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 |
| Descrizione fisica | 1 electronic resource (146 p.) |
| Soggetto topico | Technology: general issues |
| Soggetto non controllato |
Pompe disease
newborn screening diagnosis infantile onset Pompe disease late onset Pompe disease patient perspective California follow-up pseudodeficiency late-onset infantile-onset presymptomatic c.-32-13T& gt G infantile-onset Pompe disease GAA sequencing immune modulation therapy enzyme replacement therapy cross-reactive immunologic material genotype-phenotype correlation treatment and follow-up lysosomal storage diseases variant cut-off next generation sequencing dried blood spots new disorders implementation acid α-glucosidase alpha glucosidase Pompe disease diagnostics testing |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557494603321 |
Hwu Wuh-Liang
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Rheumatoid Arthritis Therapy Reappraisal : Strategies, Opportunities and Challenges
| Rheumatoid Arthritis Therapy Reappraisal : Strategies, Opportunities and Challenges |
| Autore | Müller Rüdiger |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 |
| Descrizione fisica | 1 electronic resource (260 p.) |
| Soggetto topico | Medicine |
| Soggetto non controllato |
rheumatoid arthritis
sleep sleep disorders pain osteoporosis fracture fracture risk assessment tool treat-to-target certolizumab pegol csDMARDs glucocorticoids intra-articular injections DAS 28 ACR response HAQ-DI TNFα golimumab efficacy tolerability immunogenicity methotrexate posology titration oral route subcutaneous route bioavailability effectiveness periodontitis periodontal disease anti-citrullinated protein autoantibodies rheumatoid factor smoking medication Porphyromonas gingivalis Rheumatoid arthritis matrix metalloproteinase 3 infliximab pharmacogenomics anti-TNF personalized medicine baricitinib disease-modifying antirheumatic drugs pain perception outcomes research patient perspective Rheumatoid Arthritis therapy DMARD MTX Tumor Necrosis Factor-Alpha Inhibitors ankylosing spondylitis biosimilar switching synovial fibroblasts cytokine osteoclast herbal medicine methylation next-generation sequencing recovery of function fatigue productivity tofacitinib oral Th1.17 IL-17A IFN-γ, CD73 adenosine psoriatic arthritis regulation pseudoerosions hand foot ultrasonography radiography computed tomography magnetic resonance imaging |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Rheumatoid Arthritis Therapy Reappraisal |
| Record Nr. | UNINA-9910557286503321 |
|
Müller Rüdiger
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||